11/11/2026
Would love to do the psychedelic assisted therapy training one day.
A single dose of a compound found in magic mushrooms helped 40% of patients with treatment-resistant depression reach remission within just three weeks, according to a UK clinical trial.
For people living with depression that does not improve despite multiple treatments, finding effective relief can be extremely difficult. Now, researchers at King's College London have reported encouraging results from a carefully supervised trial involving psilocybin, the psychedelic compound found in certain mushrooms.
The study, published in Nature Medicine in August 2026, involved 60 adults with treatment-resistant depression. Researchers randomly assigned 30 participants to receive a single 25-milligram dose of psilocybin and 30 to receive a placebo. Both groups received psychological preparation and support throughout treatment.
After three weeks, 40% of participants who received psilocybin were in remission, compared with just 3% in the placebo group. By six weeks, half of those given psilocybin had experienced a clinically meaningful reduction in depressive symptoms.
Psilocybin acts on serotonin receptors in the brain, particularly those involved in mood, perception and cognition. Scientists are investigating whether its effects, combined with structured psychological support, could help patients move beyond persistent patterns of depressive thinking.
What makes this research particularly important is that it was conducted within England's National Health Service (NHS), demonstrating that this experimental approach can be studied in a public healthcare setting.
However, the findings do not establish psilocybin as a proven cure. The trial involved only 60 people, followed them for six weeks, and participants could often identify which treatment they had received. Larger studies are needed to determine long-term effectiveness and safety.
The treatment also required professional supervision and careful patient screening. These results should not be interpreted as evidence that taking psychedelic mushrooms independently is a safe or effective depression treatment.
Still, the findings offer a promising direction for developing new treatments for people who have not benefited from conventional antidepressants.
Source: Rucker, J. J., et al. (2026). Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nature Medicine.